Reviewer’s report

Title: Amiodarone-induced reversible and irreversible hepatotoxicity: a case report

Version: 0 Date: 02 Feb 2018

Reviewer: Rahul Chaudhary

Reviewer's report:

1. Do you believe the case report is authentic?
   Yes

2. Do you have any ethical concerns? Please consider if local Institutional Review Board approval or ethical approval was obtained (if appropriate) and if the patient (or their parent or guardian in the case of children under 18) gave written, informed consent to publish this case and any accompanying images. A statement to this effect should appear in the manuscript.
   Comments: No concerns. Authors have mentioned about obtaining consent and IRB approval.

3. Does the Introduction explain the relevance of the case to the medical literature?
   Yes

4. Does the article report the following information? Where information is missing, please specify.
   a. The relevant patient information, including:
      - De-identified demographic information (age, gender, ethnicity): Ethnicity was not mentioned
      - Main symptoms of the patient: Yes
      - Medical, family and psychosocial history: Yes
      - Relevant past interventions and their outcomes: Yes
b. The relevant physical examination findings: No

c. Important dates and times in this case (if appropriate, organized as a timeline via a figure or table); if specific dates could lead to patient identification, consider including time relevant to initial presentation, i.e. initial presentation at T = 0, follow up at T = 1 month.

Information about the first patient and the duration of time and trend of elevation of AST/ALT are not mentioned (e.g. was it a gradual progression or were the enzyme levels intermittently elevated)

d. Diagnostic assessments, including:
   - Diagnostic methods: Yes
   - Challenges (e.g., financial, language/cultural): Yes
   - Reasoning and prognostic characteristics (e.g., staging), where applicable: Yes

e. Types and mechanism of intervention: Yes

f. A summary of the clinical course of all follow-up visits: Yes

5. Is the interpretation (discussion and conclusion) well balanced and supported by the case presented?

Comments: Yes

6. Is the anonymity of the patient protected? Please consider any identifying information in images such as facial features or nametags, whether the patient is named etc. If not, please detail below.

Yes

7. Is the Abstract representative of the case presented?

Comments: Yes
8. Does the case represent a useful contribution to the medical literature?

Comments: Yes, it does reiterate the that a closer monitoring (as mentioned in the guideline) for liver function is required in patients started on amiodarone.

9. Additional comments for the author(s)?

Page 2 line 45: "....liver CT imaging during treatment with amiodarone and liver biopsy results should be considered when amiodarone-induced hepatotoxicity is suspected". Could the authors clarify if the suggestion is to guide therapy (continuation or discontinuation of amiodarone) based on the findings of liver CT imaging and liver biopsy as it is currently unclear what the authors are trying to suggest in the conclusion section.

Page 3 line 63: "After initiation of amiodarone, liver enzymes were gradually exacerbated....". I would recommend changing exacerbated to elevated and to give a time period over which such an elevation happened including the peak and the lowest values; also was the trend towards slow progressive AST/ALT elevation or was the elevation intermittent.

Page 5 line 88: Would change the word exacerbated to elevated and provide a timeline of elevation of LFTs (would also provide the values up to which AST/ALT were elevated and if they were indeed > 5 times above upper limit of normal) since initiation of amiodarone.

Page 6, line 122: was the liver enzyme elevation in the second patient more than 5 times above upper limit of normal?

Page 7 line 133: Would mention the signs associated with hepatotoxicity with amiodarone (e.g. hepatomegaly, weakness, ascites, jaundice) and the current recommendations for discontinuation of amiodarone therapy.

**Level of interest**
Please indicate how interesting you found the manuscript:

An article of importance in its field

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal